On July 26, 2002, TLC Vision Corporation (formerly TLC Laser Eye Centers) completed a venture capital-type equity investment in Vascular Sciences Corporation. Together the companies established OccuLogix, LP, a 50/50 joint venture designed to commercialize Vascular Sciences’ Rheopheresis® blood filtration process in the U.S., Canada and Mexico. The value of the deal is undisclosed.
TLC Vision was represented by in-house counsel Kamal Mundi, and by Torys LLP with a team consisting of David Chaikof, Karrin Powys-Lybbe, John Emanoilidis, Michael Choiselat, Ron Nobrega, Robin Coster and Lesley Rapaport, and assisted by Eileen McMahon, Nicole Rosenberg and Faeron Trehearne in Toronto and Jeff Scheine and Pamela Petree (tax) and Geoff Gilbert (corporate) in New York.
Gray Cary Ware & Freidenrich, LLP in San Diego acted for Vascular Sciences, with a team that included Matt Kirmayer, Neil Balmert, Mark Wicker, Kristi Wilkens, Adam Schwenker, Randy Socol and Christian Waage.